Vifor Pharma

Vifor Pharma ROCE

Delisted·Dec 22, 2022

The Return on Capital Employed (ROCE) of Vifor Pharma (VIFN.SW) as of Nov 22, 2026 is 10.64 %. In the previous year, Return on Capital Employed (ROCE) was 6.48 % — a change of 64.22% (higher).

ROCE

10.64 %

YoY

64.22%

Last updated:

In 2021, Vifor Pharma's return on capital employed (ROCE) was 10.64 %, a 64.22% increase from the 6.48 % ROCE in the previous year.

The Vifor Pharma ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2014
20.62 CHF
Jan 1, 2015
22.56 CHF
Jan 1, 2016
15.48 CHF
Jan 1, 2017
4.03 CHF
Jan 1, 2018
6.76 CHF
Jan 1, 2019
8.70 CHF
Jan 1, 2020
6.48 CHF
Jan 1, 2021
10.64 CHF
The Vifor Pharma ROCE history
YEARROCEYoY
10.64 %+64.22%
6.48 %-25.53%
8.70 %+28.68%
6.76 %+67.78%
4.03 %-73.97%
15.48 %-31.38%
22.56 %+9.42%
20.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vifor Pharma Stock analysis

What does Vifor Pharma do? Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Vifor Pharma's Return on Capital Employed (ROCE)

Vifor Pharma's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Vifor Pharma's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Vifor Pharma's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Vifor Pharma’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Vifor Pharma stock

Return on Capital Employed (ROCE) of Vifor Pharma is 10.64 % in 2021.

Return on Capital Employed (ROCE) of Vifor Pharma changed from 6.48 % to 10.64 %, representing a 64.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Vifor Pharma since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Vifor Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Vifor Pharma

All Key Metrics — Vifor Pharma